{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:50:32Z","timestamp":1778575832356,"version":"3.51.4"},"reference-count":400,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012618","name":"National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejpb.2020.05.005","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:32:46Z","timestamp":1590010366000},"page":"130-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Preclinical challenges for developing long acting intravitreal medicines"],"prefix":"10.1016","volume":"153","author":[{"given":"Sahar","family":"Awwad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christin","family":"Henein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nkiruka","family":"Ibeanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng T.","family":"Khaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Brocchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0005","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/bjophthalmol-2017-311258","article-title":"Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: Magnitude, temporal trends and projections","volume":"102","author":"Bourne","year":"2018","journal-title":"Br. J. Ophthalmol."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b0010","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.addr.2006.07.025","article-title":"Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling","volume":"58","author":"Ranta","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2020.05.005_b0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog Retin Eye Res."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.maturitas.2010.02.006","article-title":"Age-related macular degeneration: current and novel therapies","volume":"66","author":"Prasad","year":"2010","journal-title":"Maturitas"},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b0025","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"Suppl 5","key":"10.1016\/j.ejpb.2020.05.005_b0030","first-page":"S1","article-title":"The rising global burden of diabetes and its complications: estimates and projections to the year 2010","volume":"14","author":"Amos","year":"1997","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejpb.2020.05.005_b0035","doi-asserted-by":"crossref","unstructured":"King, HilaryAubert RE, Herman WH. Prevalence, numerical estimates, and projections. Diabetes 1998; 21(9): 1414\u20131431.","DOI":"10.2337\/diacare.21.9.1414"},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajo.2011.11.022","article-title":"Changing trends of blindness: the initial harvest from translational public health and clinical research in ophthalmology","volume":"153","author":"Cheung","year":"2012","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0045","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40123-020-00230-4","article-title":"Intravitreal injections with vascular endothelial growth factor inhibitors: a practical approach","volume":"9","author":"Petri","year":"2020","journal-title":"Ophthalmol Ther."},{"key":"10.1016\/j.ejpb.2020.05.005_b0050","unstructured":"Williams G. IVT injections: health policy implications. Rev Ophthalmol. https:\/\/scholar.google.com\/scholar?q=IVT+Injections%3A+Health+Policy+Implication&btnG=&hl=en&as_sdt=0%2C39#0. Published 2014."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ophtha.2016.10.036","article-title":"Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients","volume":"124","author":"Parikh","year":"2017","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/pharmaceutics11010009","article-title":"Pharmacokinetic simulations of intravitreal biologicals: Aspects of drug delivery to the posterior and anterior segments","volume":"11","author":"Rimpel\u00e4","year":"2019","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0065","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41433-019-0434-y","article-title":"Biotherapeutics and immunogenicity: ophthalmic perspective","volume":"33","author":"Sharma","year":"2019","journal-title":"Eye."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0070","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection: a comprehensive review","volume":"24","author":"Jager","year":"2004","journal-title":"Retina."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b0075","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.drudis.2019.05.032","article-title":"The safety evaluation of long-acting ocular delivery systems","volume":"24","author":"Thackaberry","year":"2019","journal-title":"Drug Discov Today."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b0080","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.drudis.2019.05.025","article-title":"Protein conjugates and fusion proteins as ocular therapeutics","volume":"24","author":"Mehta","year":"2019","journal-title":"Drug Discov Today."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0085","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br. J. Ophthalmol."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b0090","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0095","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.survophthal.2019.02.008","article-title":"The use of real-world evidence for evaluating anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration","volume":"64","author":"Talks","year":"2019","journal-title":"Surv. Ophthalmol."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/17425247.2019.1618829","article-title":"Recent advances in slow and sustained drug release for retina drug delivery","volume":"16","author":"Behar-Cohen","year":"2019","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.ejpb.2020.05.005_b0105","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000431201","article-title":"Biologic Therapies: Anti-Tumor Necrosis Factor-\u03b1, Anti-Interleukins, Rituximab and Others","volume":"55","author":"Bhatt","year":"2016","journal-title":"Dev. Ophthalmol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0110","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/0929867326666190726121711","article-title":"Pharmacological advances in the treatment of age-related macular degeneration","volume":"27","author":"Gil-Mart\u00ednez","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejpb.2020.05.005_b0115","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1111\/bph.14024","article-title":"Principles of pharmacology in the eye","volume":"174","author":"Awwad","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b0120","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_bib1975","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_bib1976","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-019-2689-1","article-title":"In vivo stability of therapeutic proteins","volume":"37","author":"Schuster","year":"2020","journal-title":"Pharmaceut. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1248\/bpb.17.283","article-title":"In vivo\/in vitro correlation of intravitreal delivery of drugs with the help of computer simulation","volume":"17","author":"OhtoriI","year":"1994","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2020.05.005_b0130","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.simpat.2006.03.003","article-title":"Probabilistic methods for drug dissolution. Part 2. Modelling a soluble binary drug delivery system dissolving in vitro","volume":"14","author":"Barat","year":"2006","journal-title":"Simul. Model. Pract. Theory"},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0135","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1208\/s12249-008-9045-9","article-title":"Minimizing variability of cascade impaction measurements in inhalers and nebulizers","volume":"9","author":"Bonam","year":"2008","journal-title":"AAPS PharmSciTech."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/17425247.2011.543896","article-title":"In vitro and in vivo testing methods for respiratory drug delivery","volume":"8","author":"Agu","year":"2011","journal-title":"Expert Opin Drug Deliv."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11539680-000000000-00000","article-title":"Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling","volume":"50","author":"Jones","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0150","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17425250903099649","article-title":"Human clearance prediction: shifting the paradigm","volume":"5","author":"Lav\u00e9","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0155","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo drug metabolism in human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.ejpb.2020.05.005_b0160","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s11095-012-0691-y","article-title":"Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways","volume":"29","author":"Longest","year":"2012","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b0165","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1002\/jps.23317","article-title":"Formulation and in vitro \/ in vivo correlation of a drug-in-adhesive transdermal patch containing azasetron","volume":"101","author":"Sun","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b0170","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1517\/17425240903307431","article-title":"Role of in vitro release models in formulation development and quality control of parenteral depots","volume":"6","author":"Larsen","year":"2009","journal-title":"Expert Opin Drug Deliv."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0175","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12272-012-0401-7","article-title":"The relevance of polymeric synthetic membranes in topical formulation assessment and drug diffusion study","volume":"35","author":"Ng","year":"2012","journal-title":"Arch Pharm Res."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_bib1971","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.8.6.1","article-title":"Influence of charge, hydrophobicity, and size on vitreous pharmacokinetics of large molecules","volume":"8","author":"Crowell","year":"2019","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0180","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1021\/acs.molpharmaceut.6b00345","article-title":"Contribution of antibody hydrodynamic size to vitreal clearance revealed through rabbit studies using a species-matched fab","volume":"13","author":"Shatz","year":"2016","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0185","first-page":"695","article-title":"Ocular half-life of intravitreal biologics in humans and other species: meta-analysis and model-based prediction","volume":"17","author":"Caruso","year":"2020","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b0190","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13554-012-0003-4","article-title":"Aflibercept: a potent vascular endothelial growth factor antagonist for neovascular age-related macular degeneration and other retinal vascular diseases","volume":"2","author":"Sophie","year":"2012","journal-title":"Biol Ther."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40942-016-0026-y","article-title":"Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept","volume":"2","author":"de Oliveira Dias","year":"2016","journal-title":"Int. J. Retin. Vitr."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b0205","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"10153","key":"10.1016\/j.ejpb.2020.05.005_b0210","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(18)32291-8","article-title":"Age-related macular degeneration: treatment at what cost?","volume":"392","author":"Lancet","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b0215","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/eye.2016.154","article-title":"Licence to save: a UK survey of anti-VEGF use for the eye in 2015","volume":"30","author":"Shalaby","year":"2016","journal-title":"Eye."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0220","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/bjo.2007.116616","article-title":"Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness","volume":"91","author":"Raftery","year":"2007","journal-title":"Br. J. Ophthalmol."},{"issue":"18","key":"10.1016\/j.ejpb.2020.05.005_b0225","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","article-title":"Brolucizumab: first approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.ejpb.2020.05.005_b0230","unstructured":"Ung BC, Agranat J, Yonekawa Y. The fight against neovascular AMD. An update on the weapons in the works. Ophthalmol Manage. 2019;(July 1, 2019)."},{"key":"10.1016\/j.ejpb.2020.05.005_b0235","unstructured":"Novartis. New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval. https:\/\/www.novartis.com\/news\/media-releases\/new-novartis-phase-iii-data-brolucizumab-demonstrate-reliability-12-week-treatment-interval. Published 2018."},{"key":"10.1016\/j.ejpb.2020.05.005_b0240","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2147\/OPTH.S184706","article-title":"Brolucizumab: Evidence to date in the treatment of neovascular age-related macular degeneration","volume":"13","author":"Yannuzzi","year":"2019","journal-title":"Clin Ophthalmol."},{"issue":"April","key":"10.1016\/j.ejpb.2020.05.005_b0245","article-title":"Severe vision loss secondary to retinal arteriolar occlusion after multiple intravitreal brolucizumab administrations","volume":"18","author":"Jain","year":"2020","journal-title":"Am. J. Ophthalmol. Case Reports."},{"issue":"March","key":"10.1016\/j.ejpb.2020.05.005_b0250","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"Am. J. Ophthalmol. Case Reports."},{"key":"10.1016\/j.ejpb.2020.05.005_b0255","first-page":"13","article-title":"Brolucizumab and immunogenicity","author":"Sharma","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.ejpb.2020.05.005_b0260","unstructured":"Molecular Partners. Allergan and molecular partners announce two positive phase 3 clinical trials for abicipar pegol 8 and 12-week regimens for the treatment in patients with neovascular age-related macular degeneration. https:\/\/www.molecularpartners.com\/allergan-and-molecular-partners-announce-two-positive-phase-3-clinical-trials-for-abicipar-pegol-8-and-12-week-regimens-for-the-treatment-in-patients-with-neovascular-age-related-macular-degeneration\/. Published 2018."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b0265","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17425247.2019.1553953","article-title":"Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases","volume":"16","author":"Shatz","year":"2019","journal-title":"Expert Opin Drug Deliv."},{"issue":"15","key":"10.1016\/j.ejpb.2020.05.005_b0275","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1080\/14656566.2019.1636031","article-title":"Innovative therapies for neovascular age-related macular degeneration","volume":"20","author":"Al-Khersan","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0280","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","article-title":"Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients","volume":"31","author":"Boyer","year":"2011","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b0285","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0b013e31827e247b","article-title":"Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients","volume":"33","author":"Ad\u00e1n","year":"2013","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0290","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/jop.2014.0010","article-title":"Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema","volume":"30","author":"Medeiros","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0295","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/eye.2015.281","article-title":"Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes","volume":"30","author":"Kumar","year":"2016","journal-title":"Eye."},{"key":"10.1016\/j.ejpb.2020.05.005_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.10.026","article-title":"Single ocular injection of a sustained-release anti -VEGF delivers 6 months pharmacokinetics and ef fi cacy in a primate laser CNV model","volume":"244","author":"Adamson","year":"2016","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0305","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1080\/02713683.2017.1302590","article-title":"In vivo efficacy of an injectable microsphere-hydrogel ocular drug delivery system","volume":"42","author":"Osswald","year":"2017","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2020.05.005_b0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2017.12.019","article-title":"Antibody loaded collapsible hyaluronic acid hydrogels for intraocular delivery","volume":"124","author":"Egbu","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.05.005_b0315","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejpb.2014.12.029","article-title":"Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics","volume":"95","author":"Lovett","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0320","doi-asserted-by":"crossref","first-page":"1700255","DOI":"10.1002\/mabi.201700255","article-title":"Comparative study of in situ loaded antibody and PEG-Fab NIPAAM gels","volume":"18","author":"Awwad","year":"2018","journal-title":"Macromol. Biosci."},{"issue":"March","key":"10.1016\/j.ejpb.2020.05.005_b0325","article-title":"In situ antibody-loaded hydrogel for intravitreal delivery","volume":"137","author":"Awwad","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20133","key":"10.1016\/j.ejpb.2020.05.005_b0330","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1163\/092050609X12578498952315","article-title":"Role of thermo-responsiveness and poly(ethylene glycol) diacrylate cross-link density on protein release from poly(n-isopropylacrylamide) hydrogels","volume":"22","author":"Drapala","year":"2011","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"14","key":"10.1016\/j.ejpb.2020.05.005_b0335","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1016\/j.biomaterials.2011.01.058","article-title":"The effects of cross-linked thermo-responsive PNIPAAm-based hydrogel injection on retinal function","volume":"32","author":"Turturro","year":"2011","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.4.2.5","article-title":"Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study","volume":"4","author":"Yu","year":"2015","journal-title":"Transl Vis. Sci. Technol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0345","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1167\/iovs.13-13120","article-title":"Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo","volume":"55","author":"Rauck","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b0350","first-page":"1941","article-title":"Controlled release bevacizumab in thermoresponsive hydrogel found to inhibit angiogenesis","volume":"24","author":"Hu","year":"2014","journal-title":"Biomed. Mater. Eng."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0355","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bm2009558","article-title":"Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel","volume":"13","author":"Wang","year":"2012","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/tvst.7.4.21","article-title":"A controlled release system for long-acting intravitreal delivery of small molecules","volume":"7","author":"Machinaga","year":"2018","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0365","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/jop.2010.0158","article-title":"Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model","volume":"27","author":"Pan","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2020.05.005_b0370","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.actbio.2017.10.015","article-title":"Electrospun formulations of bevacizumab for sustained release in the eye","volume":"64","author":"Angkawinitwong","year":"2017","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0375","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jfb4010014","article-title":"Design and in vitro biocompatibility of a novel ocular drug delivery device","volume":"4","author":"Gooch","year":"2013","journal-title":"J. Funct. Biomater."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0380","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","article-title":"Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration","volume":"29","author":"Abrishami","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ejpb.2020.05.005_b0385","doi-asserted-by":"crossref","first-page":"14837","DOI":"10.1038\/ncomms14837","article-title":"Long-acting protein drugs for the treatment of ocular diseases","volume":"8","author":"Ghosh","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2020.05.005_b0390","unstructured":"S.S.H. Awwad, The vitreous as a depot to prolong the action of ocular therapies, 2016."},{"key":"10.1016\/j.ejpb.2020.05.005_b0395","unstructured":"Huelsmann PM, Kopetzki E. WO 2017\/211731 Al, Fusion proteins for ophthalmology with increased eye retention. 2017; (12): 1\u201369."},{"key":"10.1016\/j.ejpb.2020.05.005_b0400","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jconrel.2015.09.065","article-title":"Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions","volume":"219","author":"Delplace","year":"2015","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0405","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/antib2030452","article-title":"Developments and challenges for mAb-based therapeutics","volume":"2","author":"Goswami","year":"2013","journal-title":"Antibodies"},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0410","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/pharmaceutics10030083","article-title":"Overview of antibody drug delivery","volume":"10","author":"Awwad","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.05.005_b0415","unstructured":"European Medicines Agency (EMA). Assessment Report. Eylea. International Non-Proprietary Name: AFLIBERCEPT. Procedure No. EMEA\/H\/C\/002392\/II\/0009.; 2014."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b0420","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2011.03.020","article-title":"The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2020.05.005_b0425","unstructured":"European Medical Agency. Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for in Vivo Clinical Use. London, 2012."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b0430","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4155\/bio-2018-0047","article-title":"Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection","volume":"10","author":"Wessels","year":"2018","journal-title":"Bioanalysis."},{"key":"10.1016\/j.ejpb.2020.05.005_b0435","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.yrtph.2017.03.013","article-title":"Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics","volume":"86","author":"de Zafra","year":"2017","journal-title":"Regul. Toxicol. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b0440","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1208\/s12248-017-0128-y","article-title":"Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space","volume":"19","author":"Wakshull","year":"2017","journal-title":"AAPS J."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b0445","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Ghasemi Falavarjani","year":"2013","journal-title":"Eye."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b0450","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ophtha.2012.12.009","article-title":"Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: One-year outcomes and investigative results","volume":"120","author":"Goldberg","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b0455","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaophthalmol.2013.88","article-title":"An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone","volume":"131","author":"Sheyman","year":"2013","journal-title":"JAMA Ophthalmol."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0460","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40264-015-0273-0","article-title":"Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration","volume":"38","author":"Modi","year":"2015","journal-title":"Drug Saf."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0465","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamaophthalmol.2015.2556","article-title":"Association of compounded bevacizumab with postinjection endophthalmitis","volume":"133","author":"VanderBeek","year":"2015","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0470","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv. Ophthalmol."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0475","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s11095-011-0523-5","article-title":"Immunogenicity of therapeutic proteins: the use of animal models","volume":"28","author":"Brinks","year":"2011","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b0480","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.preteyeres.2010.04.003","article-title":"Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics","volume":"29","author":"Laude","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ejpb.2020.05.005_b0485","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data","volume":"137","author":"del Amo","year":"2015","journal-title":"Exp. Eye Res."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0490","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1167\/iovs.13-13707","article-title":"Drug and gene delivery to the back of the eye: From bench to bedside","volume":"55","author":"Rowe-Rendleman","year":"2014","journal-title":"Investig Ophthalmol Vis Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b0495","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2\u20133","key":"10.1016\/j.ejpb.2020.05.005_b0500","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-409X(00)00112-5","article-title":"Microdialysis and drug delivery to the eye","volume":"45","author":"Rittenhouse","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0505","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0192623307310955","article-title":"Safety evaluation of ocular drug delivery formulations: techniques and practical considerations","volume":"36","author":"Short","year":"2008","journal-title":"Toxicol. Pathol."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0510","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/17425247.2014.927864","article-title":"Intravitreal drug delivery in retinal disease: are we out of our depth?","volume":"11","author":"Thakur","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0515","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2020.05.005_b0520","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0014-4835(02)00311-1","article-title":"Disposition of short-chain aliphatic alcohols in rabbit vitreous by ocular microdialysis","volume":"76","author":"Atluri","year":"2003","journal-title":"Exp. Eye Res."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b0525","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0530","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/IAE.0b013e318134eecd","article-title":"Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits","volume":"27","author":"Gaudreault","year":"2007","journal-title":"Retina."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0535","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: A population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0540","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0545","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1167\/iovs.09-4140","article-title":"Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes","volume":"51","author":"Miyake","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0550","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1097\/IAE.0b013e318217373c","article-title":"Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans","volume":"31","author":"Meyer","year":"2011","journal-title":"Retina."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2008.04.023","article-title":"Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization","volume":"115","author":"Zhu","year":"2008","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0560","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0565","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/17512433.2014.884458","article-title":"Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF","volume":"7","author":"Stewart","year":"2014","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_bib1972","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000499529","article-title":"A prediction model for the intraocular pharmacokinetics of intravitreally injected drugs based on molecular physicochemical properties","volume":"63","author":"Kim","year":"2020","journal-title":"Ophthal. Res."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0570","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1021\/acs.molpharmaceut.9b00679","article-title":"Intravitreal Pharmacokinetics in Mice: SPECT\/CT Imaging and Scaling to Rabbits and Humans","volume":"16","author":"Schmitt","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2020.05.005_b0575","first-page":"391","article-title":"The flow of aqueous humor in the human eye","volume":"80","author":"Brubaker","year":"1982","journal-title":"Trans. Am. Ophthalmol. Soc."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0580","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9394(98)00436-X","article-title":"Aqueous humor dynamics in the aging human eye","volume":"127","author":"Toris","year":"1999","journal-title":"Am. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0585","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2460\/ajvr.73.5.704","article-title":"Evaluation of the aqueous humor flow rate in the eyes of clinically normal cats by use of fluorophotometry","volume":"73","author":"Crumley","year":"2012","journal-title":"Am. J. Vet. Res."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b0590","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2460\/ajvr.73.7.1074","article-title":"Effects of ocular administration of ophthalmic 2% dorzolamide hydrochloride solution on aqueous humor flow rate and intraocular pressure in clinically normal cats","volume":"73","author":"Rankin","year":"2012","journal-title":"Am. J. Vet. Res."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0595","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1463-5224.2005.00401.x","article-title":"Ocular parameters related to drug delivery in the canine and equine eye: aqueous and vitreous humor volume and scleral surface area and thickness","volume":"8","author":"Gilger","year":"2005","journal-title":"Vet Ophthalmol."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0600","first-page":"1498","article-title":"Aqueous humor flow measured with fluorophotometry in timolol-treated primates","volume":"29","author":"Bartels","year":"1988","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b0605","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1167\/iovs.03-0504","article-title":"Aqueous humor dynamics in mice","volume":"44","author":"Aihara","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0610","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1089\/jop.2006.0057","article-title":"A modified in vitro method for aqueous humor outflow studies in enucleated porcine eyes","volume":"23","author":"Vaajanen","year":"2007","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0615","first-page":"84","article-title":"The rate of aqueous humor formation in buphthalmic rabbit eyes","volume":"6","author":"McMaster","year":"1967","journal-title":"Invest. Ophthalmol."},{"key":"10.1016\/j.ejpb.2020.05.005_b0620","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1007\/BF02343072","article-title":"Aqueous humor dynamics in rats","volume":"234","author":"Mermoud","year":"1996","journal-title":"Graefe\u2019s Arch Clin. Exp. Ophthalmol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0625","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/108076801753162807","article-title":"Review: practical issues in intravitreal drug delivery","volume":"17","author":"Maurice","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2020.05.005_b0630","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev-fluid-120710-101058","article-title":"Fluid mechanics of the eye","volume":"44","author":"Siggers","year":"2012","journal-title":"Annu. Rev. Fluid Mech."},{"key":"10.1016\/j.ejpb.2020.05.005_b0635","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.bioeng.6.040803.140055","article-title":"Ocular biomechanics and biotransport","volume":"6","author":"Ethier","year":"2004","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.ejpb.2020.05.005_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ejpb.2020.05.005_b0645","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archopht.1992.01080140115038","article-title":"Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection","volume":"110","author":"Kwak","year":"1992","journal-title":"Arch. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0650","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11095-012-0847-9","article-title":"Retina-choroid-sclera permeability for ophthalmic drugs in the vitreous to blood direction: quantitative assessment","volume":"30","author":"Haghjou","year":"2013","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0655","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/jps.21987","article-title":"A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases","volume":"99","author":"Choonara","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2020.05.005_b0660","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02569055","article-title":"The blood-ocular barriers: past, present, and future","volume":"93","author":"Cunha-Vaz","year":"1997","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.ejpb.2020.05.005_b0665","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.exer.2005.09.018","article-title":"The pharmacokinetics of rituximab following an intravitreal injection","volume":"82","author":"Kim","year":"2006","journal-title":"Exp. Eye Res."},{"issue":"14","key":"10.1016\/j.ejpb.2020.05.005_b0670","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.addr.2005.09.004","article-title":"Topical and systemic drug delivery to the posterior segments","volume":"57","author":"Hughes","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0675","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration","volume":"40","author":"Do","year":"2019","journal-title":"Retina."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b0680","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1167\/iovs.15-17279","article-title":"Ranibizumab and aflibercept: Intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes","volume":"56","author":"Niwa","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"13","key":"10.1016\/j.ejpb.2020.05.005_b0685","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1167\/iovs.17-22431","article-title":"Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model","volume":"58","author":"Christoforidis","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0690","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/eye.2014.329","article-title":"Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model","volume":"29","author":"Park","year":"2015","journal-title":"Eye."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b0695","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1167\/iovs.16-19204","article-title":"Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model","volume":"57","author":"Park","year":"2016","journal-title":"Investig. Opthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b0700","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3109\/02713683.2012.727521","article-title":"Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET\/CT","volume":"37","author":"Christoforidis","year":"2012","journal-title":"Curr. Eye Res."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0705","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2020.05.005_b0710","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/OPTH.S19555","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits","volume":"5","author":"Sinapis","year":"2011","journal-title":"Clin Ophthalmol."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b0715","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/jop.2013.0009","article-title":"Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes","volume":"29","author":"Ahn","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0720","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1167\/iovs.03-1110","article-title":"Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema","volume":"45","author":"Audren","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0725","first-page":"681","article-title":"Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection","volume":"110","author":"Beer","year":"2003","journal-title":"Am Acad Ophthalmol."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b0730","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.ophtha.2009.01.039","article-title":"Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection","volume":"116","author":"Cheng","year":"2009","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0735","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00006982-200507000-00002","article-title":"Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes","volume":"25","author":"Chin","year":"2005","journal-title":"Retina."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0740","first-page":"437","article-title":"Vitreous substitutes: Challenges and directions","volume":"8","author":"Gao","year":"2015","journal-title":"Int J Ophthalmol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0745","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00397-017-0997-0","article-title":"Rheological behaviour of vitreous humour","volume":"56","author":"Silva","year":"2017","journal-title":"Rheol. Acta"},{"key":"10.1016\/j.ejpb.2020.05.005_b0750","doi-asserted-by":"crossref","unstructured":"Panova IG, Tatikolov AS. Characterization of the vitreous body of the human eye using a cyanine dye as a spectral and fluorescent probe, in: F. Manns, P.G. S\u00f6derberg, A. Ho, eds. Proceedings of SPIE - The International Society for Optical Engineering 7163, Vol 7163, 2009.","DOI":"10.1117\/12.808400"},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0755","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1350-9462(99)00016-6","article-title":"Structural macromolecules and supramolecular organisation of the vitreous gel","volume":"19","author":"Bishop","year":"2000","journal-title":"Prog. Retin. Eye Res."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0760","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/eye.2008.21","article-title":"Adult vitreous structure and postnatal changes","volume":"22","author":"Le Goff","year":"2008","journal-title":"Eye."},{"key":"10.1016\/j.ejpb.2020.05.005_b0765","unstructured":"E.A. Balazs, Functional anatomy of the vitreous, in: T. Duane, E. Jaeger, eds. Biomedical Foundation of Ophthalmology, Vol 1.; 1984:14."},{"key":"10.1016\/j.ejpb.2020.05.005_b0770","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/eye.1992.120","article-title":"The chemical morphology of the vitreous","volume":"6","author":"Scott","year":"1992","journal-title":"Eye."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0775","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.exer.2004.11.014","article-title":"Packages of vitreous collagen (type II) in the human retina: an indication of postnatal collagen turnover?","volume":"80","author":"Ponsioen","year":"2005","journal-title":"Exp. Eye Res."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0780","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jbiomech.2010.10.002","article-title":"Rheology of the vitreous gel: effects of macromolecule organization on the viscoelastic properties","volume":"44","author":"Sharif-Kashani","year":"2011","journal-title":"J. Biomech."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b0785","first-page":"1867","article-title":"Morphology and ultrastructure of human vitreous fibers","volume":"30","author":"Sebag","year":"1989","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"07","key":"10.1016\/j.ejpb.2020.05.005_b0790","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4236\/jbise.2013.67091","article-title":"Structure of vitreous body and its relationship with liquefaction","volume":"06","author":"Kodama","year":"2013","journal-title":"J. Biomed. Sci. Eng."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0795","first-page":"2680","article-title":"Distribution of collagen IV in human ocular tissues","volume":"34","author":"Ishizaki","year":"1993","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_bib1973","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/02713683.2019.1565890","article-title":"Morphology and composition of the inner limiting membrane: species-specific variations and relevance toward drug delivery research","volume":"44","author":"Peynshaert","year":"2019","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2020.05.005_b0800","doi-asserted-by":"crossref","unstructured":"M.A. Karsdal, Introduction, in: Biochemistry of Collagens, Laminins and Elastin. Elsevier, 2016, xix\u2013xxxiv.","DOI":"10.1016\/B978-0-12-809847-9.02001-8"},{"key":"10.1016\/j.ejpb.2020.05.005_b0805","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/eye.1998.257","article-title":"An immunohistochemical study of collagens in trachoma and vernal keratoconjunctivitis","volume":"12","author":"Abu el-Asrar","year":"1998","journal-title":"Eye."},{"key":"10.1016\/j.ejpb.2020.05.005_b0810","first-page":"2283","article-title":"Structure of corneal layers, collagen fibrils, and proteoglycans of tree shrew cornea","volume":"17","author":"Almubrad","year":"2011","journal-title":"Mol Vis."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b0815","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1167\/iovs.07-1456","article-title":"Collagen distribution in the human vitreoretinal interface","volume":"49","author":"Ponsioen","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2020.05.005_b0820","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0014-4835(74)90117-1","article-title":"Collagen heterogeneity in the avian eye: lens, vitreous body, cornea and sclera","volume":"18","author":"Kang","year":"1974","journal-title":"Exp Eye Res."},{"key":"10.1016\/j.ejpb.2020.05.005_b0825","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/bjo.71.12.886","article-title":"Collagen distribution in the lamina cribrosa and the trabecular meshwork of the human eye","volume":"71","author":"Rehnberg","year":"1987","journal-title":"Br. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0830","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1679\/aohc.46.589","article-title":"Biology of collagen-proteoglycan interaction","volume":"46","author":"Junqueira","year":"1983","journal-title":"Arch Histol Jpn."},{"key":"10.1016\/j.ejpb.2020.05.005_b0835","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-4835(64)80003-8","article-title":"The chemical composition of the human vitreous body as related to age and Myopia","volume":"3","author":"Berman","year":"1964","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2020.05.005_b0840","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/eye.1996.159","article-title":"The biochemical structure of mammalian vitreous","volume":"10","author":"Bishop","year":"1996","journal-title":"Eye."},{"key":"10.1016\/j.ejpb.2020.05.005_b0845","article-title":"The vitreous humor as a barrier to nanoparticle distribution","author":"Mains","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2020.05.005_b0850","first-page":"497","article-title":"Extraction and characterization of the tissue forms of collagen types II and IX from bovine vitreous","volume":"Pt 2","author":"Bishop","year":"1994299","journal-title":"Biochem. J."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b0855","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1073\/pnas.73.12.4420","article-title":"a. Synthesis of type II collagen in vitro by embryonic chick neural retina tissue","volume":"73","author":"Smith","year":"1976","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0860","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/exer.2000.0972","article-title":"Age-dependent changes in the expression of matrix components in the mouse eye","volume":"72","author":"Ihanam\u00e4ki","year":"2001","journal-title":"Exp. Eye Res."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0865","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0014-4835(92)90051-S","article-title":"An immunoelectron microscope study of the aged human lens capsule","volume":"54","author":"Marshall","year":"1992","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2020.05.005_b0870","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1755-3768.1985.tb06856.x","article-title":"A comparative analysis of the collagen type and distribution in the trabecular meshwork, sclera, lamina cribrosa and the optic nerve in the human eye","volume":"173","author":"Tengroth","year":"1985","journal-title":"Acta Ophthalmol. Suppl. (Oxf)."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0875","first-page":"376","article-title":"Human corneal stroma contains three distinct collagens","volume":"22","author":"Newsome","year":"1982","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b0880","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1111\/j.1755-3768.2012.02481.x","article-title":"Differences in basement membrane zone components of normal conjunctiva, conjunctiva in glaucoma and normal skin","volume":"90","author":"Messmer","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2020.05.005_b0885","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/bjo.77.8.515","article-title":"Collagens in ocular tissues","volume":"77","author":"Marshall","year":"1993","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b0890","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1369\/jhc.4A6267.2004","article-title":"Presence of collagen IV in the ciliary zonules of the human eye: an immunohistochemical study by LM and TEM","volume":"52","author":"Los","year":"2004","journal-title":"J. Histochem. Cytochem."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0895","first-page":"417","article-title":"Localization of type V collagen and type IV collagen in human cornea, lung, and skin. Immunohistochemical evidence by anti-collagen antibodies characterized by immunoelectroblotting","volume":"116","author":"Konomi","year":"1984","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b0900","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1177\/41.10.8245404","article-title":"Keratan sulfate and dermatan sulfate proteoglycans associate with type VI collagen in fetal rabbit cornea","volume":"41","author":"Takahashi","year":"1993","journal-title":"J. Histochem. Cytochem."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b0905","first-page":"2408","article-title":"Type XII collagen contributes to diversities in human corneal and limbal extracellular matrices","volume":"38","author":"Wessel","year":"1997","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0910","first-page":"760","article-title":"Heterogeneity of collagens in rabbit cornea: type VI collagen","volume":"29","author":"Cintron","year":"1988","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b0915","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/BF00292358","article-title":"Type VI collagen is present in human and bovine vitreous","volume":"234","author":"Bishop","year":"1996","journal-title":"Graefe\u2019s Arch Clin. Exp. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0920","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00003226-199605000-00010","article-title":"The immunohistochemical composition of the human corneal basement membrane","volume":"15","author":"Tuori","year":"1996","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b0925","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/bjo.2003.031989","article-title":"Immunolocalisation of opticin in the human eye","volume":"88","author":"Ramesh","year":"2004","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b0930","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/07853890109002055","article-title":"Collagens and collagen-related diseases","volume":"33","author":"Myllyharju","year":"2001","journal-title":"Ann. Med."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0935","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1167\/iovs.03-1017","article-title":"Age-related changes on the surface of vitreous collagen fibrils","volume":"45","author":"Bishop","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0940","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1083\/jcb.109.2.939","article-title":"Immunoidentification of type XII collagen in embryonic tissues","volume":"109","author":"Sugrue","year":"1989","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0945","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1006\/exer.1998.0826","article-title":"Type XIII collagen is widely expressed in the adult and developing human eye and accentuated in the ciliary muscle, the optic nerve and the neural retina","volume":"70","author":"Sandberg-Lall","year":"2000","journal-title":"Exp. Eye Res."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b0950","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0040-8166(96)80004-8","article-title":"Tissue distribution and developmental expression of type XVI collagen in the mouse","volume":"28","author":"Lai","year":"1996","journal-title":"Tissue Cell"},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b0955","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.preteyeres.2004.04.002","article-title":"Collagens and collagen-related matrix components in the human and mouse eye","volume":"23","author":"Ihanam\u00e4ki","year":"2004","journal-title":"Prog Retin Eye Res."},{"issue":"25","key":"10.1016\/j.ejpb.2020.05.005_b0960","doi-asserted-by":"crossref","first-page":"23120","DOI":"10.1074\/jbc.M009912200","article-title":"alpha 1(Xx) collagen, a new member of the collagen subfamily, fibril-associated collagens with interrupted triple helices","volume":"276","author":"Koch","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.ejpb.2020.05.005_b0965","doi-asserted-by":"crossref","first-page":"20989","DOI":"10.1074\/jbc.M210616200","article-title":"Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells","volume":"278","author":"Banyard","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0970","first-page":"434","article-title":"Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)","volume":"32","author":"Stewart","year":"2012","journal-title":"Retina."},{"issue":"44","key":"10.1016\/j.ejpb.2020.05.005_b0975","doi-asserted-by":"crossref","first-page":"43236","DOI":"10.1074\/jbc.M302112200","article-title":"Collagen XXIV, a vertebrate fibrillar collagen with structural features of invertebrate collagens: selective expression in developing cornea and bone","volume":"278","author":"Koch","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2020.05.005_b0980","first-page":"462","article-title":"Distribution of free amino acids in human intraocular fluids","volume":"68","author":"Durham","year":"1970","journal-title":"Trans. Am. Ophthalmol. Soc."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b0985","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2020.05.005_b0990","doi-asserted-by":"crossref","first-page":"36150","DOI":"10.1155\/2007\/36150","article-title":"A role for excitatory amino acids in diabetic eye disease","volume":"2007","author":"Pulido","year":"2007","journal-title":"Exp Diabetes Res."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b0995","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1167\/iovs.12-10797","article-title":"Mapping the differential distribution of proteoglycan core proteins in the adult human retina, choroid, and sclera","volume":"53","author":"Keenan","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1000","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1292\/jvms.10-0201","article-title":"Spatiotemporal distribution of chondroitin sulfate proteoglycans in the developing mouse retina and optic nerve","volume":"73","author":"Ali","year":"2011","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.ejpb.2020.05.005_b1005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1350-9462(02)00009-5","article-title":"Proteoglycans in retina","volume":"21","author":"Inatani","year":"2002","journal-title":"Prog Retin Eye Res."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b1010","first-page":"1930","article-title":"Inhibitory effects of neurocan and phosphacan on neurite outgrowth from retinal ganglion cells in culture","volume":"42","author":"Inatani","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.exer.2004.05.016","article-title":"Developmental changes of aggrecan, versican and neurocan in the retina and optic nerve","volume":"79","author":"Popp","year":"2004","journal-title":"Exp. Eye Res."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0945-053X(98)90085-3","article-title":"The large chondroitin sulphate proteoglycan versican in mammalian vitreous","volume":"17","author":"Reardon","year":"1998","journal-title":"Matrix Biol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0300-9084(02)01389-5","article-title":"Karamanos NK, Theocharis D a. Pig vitreous gel: macromolecular composition with particular reference to hyaluronan-binding proteoglycans","volume":"84","author":"Noulas","year":"2002","journal-title":"Biochimie"},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b1030","first-page":"1783","article-title":"Expression of proteoglycan decorin in neural retina","volume":"40","author":"Inatani","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1035","first-page":"838","article-title":"Chondroitin sulfate proteoglycan distribution in the primate optic nerve head","volume":"35","author":"Morrison","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b1040","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1074\/jbc.270.7.3392","article-title":"Agrin is a Heparin Sulfate Proteoglycan","volume":"270","author":"Tsen","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1045","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1167\/iovs.02-0783","article-title":"Ocular and scleral alterations in gene-targeted lumican-fibromodulin double-null mice","volume":"44","author":"Chakravarti","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2020.05.005_b1050","doi-asserted-by":"crossref","unstructured":"Corpuz LM, Funderburgh JL, Funderburgh ML, Bottomley GS, Prakash S, Conrad GW. Molecular cloning and tissue distribution of keratocan. J Biol Chem. 1996; 271(16): 9759\u20139763.","DOI":"10.1074\/jbc.271.16.9759"},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1167\/iovs.09-3612","article-title":"Association of the lumican gene functional 3\u2019-UTR polymorphism with high myopia","volume":"51","author":"Lin","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1060","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.matbio.2010.04.002","article-title":"Molecular interactions in the retinal basement membrane system: a proteomic approach","volume":"29","author":"Balasubramani","year":"2010","journal-title":"Matrix Biol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1432-0436.2005.00055.x","article-title":"Ribozyme-mediated perlecan knockdown impairs chondrogenic differentiation of C3H10T1\/2 fibroblasts","volume":"74","author":"Gomes","year":"2006","journal-title":"Differentiation."},{"issue":"16","key":"10.1016\/j.ejpb.2020.05.005_b1070","doi-asserted-by":"crossref","first-page":"12304","DOI":"10.1016\/S0021-9258(17)32716-3","article-title":"Core protein structure and sequence determine the site and presence of heparan sulfate and chondroitin sulfate on syndecan-l","volume":"269","author":"Kokenyesi","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2796.1997.00170.x","article-title":"Hyaluronan: its nature, distribution, functions and turnover","volume":"242","author":"Fraser","year":"1997","journal-title":"J. Intern. Med."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b1080","doi-asserted-by":"crossref","first-page":"397","DOI":"10.17221\/1930-VETMED","article-title":"Hyaluronic acid (hyaluronan): A review","volume":"53","author":"Necas","year":"2008","journal-title":"Vet. Med. (Praha)."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1085","first-page":"486","article-title":"Localization of elastin in the normal and glaucomatous human trabecular meshwork","volume":"35","author":"Umihira","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jsb.2009.11.004","article-title":"Collagen and mature elastic fibre organisation as a function of depth in the human cornea and limbus","volume":"169","author":"Kamma-Lorger","year":"2010","journal-title":"J. Struct. Biol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1095","first-page":"563","article-title":"Ultrahistochemical studies on tangential sections of the trabecular meshwork in normal and glaucomatous eyes","volume":"21","author":"L\u00fctjen-Drecoll","year":"1981","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"25","key":"10.1016\/j.ejpb.2020.05.005_b1100","doi-asserted-by":"crossref","first-page":"17900","DOI":"10.1016\/S0021-9258(19)37127-3","article-title":"The anchoring filament protein kalinin is synthesized and secreted as a high molecular weight precursor","volume":"267","author":"Marinkovich","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/(SICI)1097-0177(199708)209:4<367::AID-AJA4>3.0.CO;2-G","article-title":"Kurpakus M a. Localization of basement membrane-associated protein isoforms during development of the ocular surface of mouse eye","volume":"209","author":"Qin","year":"1997","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.ejpb.2020.05.005_b1110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/378641","article-title":"Distribution of Nidogen in the Murine Eye and Ocular Phenotype of the Nidogen-1 Knockout Mouse","volume":"2012","author":"May","year":"2012","journal-title":"ISRN Ophthalmol."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1115","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1167\/iovs.03-0952","article-title":"Human Amniotic Membrane, Like Corneal Epithelial Basement Membrane, Manifests the 5 Chain of Type IV Collagen","volume":"45","author":"Endo","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b1120","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1074\/jbc.275.10.6945","article-title":"SPACRCAN, a Novel Human Interphotoreceptor Matrix Hyaluronan-binding Proteoglycan Synthesized by Photoreceptors and Pinealocytes","volume":"275","author":"Acharya","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1125","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1042\/bst0270832","article-title":"VIT-1: the second member of a new branch of the von Willebrand factor A domain superfamily","volume":"27","author":"Mayne","year":"1999","journal-title":"Biochem. Soc. Trans."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/elps.1150170218","article-title":"Quantitative analysis of hyaluronan in human synovial fluid using capillary electrophoresis","volume":"17","author":"Grimshaw","year":"1996","journal-title":"Electrophoresis"},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1135","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0014-4835(83)90042-8","article-title":"The molecular weight of hyaluronate in the aqueous humour and vitreous body of rabbit and cattle eyes","volume":"36","author":"Laurent","year":"1983","journal-title":"Exp. Eye Res."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1140","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/eye.1987.45","article-title":"Ageing of the vitreous","volume":"1","author":"Sebag","year":"1987","journal-title":"Eye."},{"issue":"34","key":"10.1016\/j.ejpb.2020.05.005_b1145","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1039\/b506989k","article-title":"Injectable biodegradable hydrogels composed of hyaluronic acid tyramine conjugates for drug delivery and tissue engineering","volume":"53","author":"Kurisawa","year":"2005","journal-title":"Chem. Commun."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.biomaterials.2004.02.018","article-title":"Characterization of protein release from photocrosslinkable hyaluronic acid-polyethylene glycol hydrogel tissue engineering scaffolds","volume":"26","author":"Leach","year":"2005","journal-title":"Biomaterials"},{"issue":"1\u20133","key":"10.1016\/j.ejpb.2020.05.005_b1155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0168-3659(01)00557-0","article-title":"Temperature-responsive and degradable hyaluronic acid\/Pluronic composite hydrogels for controlled release of human growth hormone","volume":"80","author":"Kim","year":"2002","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1747-0285.2008.00741.x","article-title":"The structure of glycosaminoglycans and their interactions with proteins","volume":"72","author":"Gandhi","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b1165","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3174\/ajnr.A2543","article-title":"Diffusion changes in the vitreous humor of the eye during aging","volume":"32","author":"Meral","year":"2011","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b1170","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jbiomech.2008.04.015","article-title":"Rheological properties of the vitreous and the role of hyaluronic acid","volume":"41","author":"Nickerson","year":"2008","journal-title":"J. Biomech."},{"key":"10.1016\/j.ejpb.2020.05.005_b1175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF02160337","article-title":"Age-related changes in human vitreous structure","volume":"225","author":"Sebag","year":"1987","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol."},{"issue":"C","key":"10.1016\/j.ejpb.2020.05.005_b1180","first-page":"476","article-title":"Fractionation of hyaluronic acid the polydispersity of hyaluronic acid from the bovine vitreous body","volume":"42","author":"Laurent","year":"1960","journal-title":"BBA"},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b1185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/bmc.336","article-title":"Variations in content and structure of glycosaminoglycans of the vitreous gel from different mammalian species","volume":"18","author":"Noulas","year":"2004","journal-title":"Biomed. Chromatogr."},{"issue":"6279","key":"10.1016\/j.ejpb.2020.05.005_b1190","doi-asserted-by":"crossref","first-page":"aac4750","DOI":"10.1126\/science.aac4750","article-title":"Designer protein delivery: From natural to engineered affinity-controlled release systems","volume":"351","author":"Pakulska","year":"2016","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b1195","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/bm501084u","article-title":"Affinity-based drug delivery systems for tissue repair and regeneration","volume":"15","author":"Vulic","year":"2014","journal-title":"Biomacromolecules"},{"issue":"November 2018","key":"10.1016\/j.ejpb.2020.05.005_b1200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2018.11.012","article-title":"Controlled release strategy designed for intravitreal protein delivery to the retina","volume":"293","author":"Delplace","year":"2019","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b1205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0134325","article-title":"The ultrastructural localization of type II, IV, and VI collagens at the vitreoretinal interface","volume":"10","author":"Bu","year":"2015","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b1210","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.addr.2003.08.002","article-title":"Collagens - Structure, function, and biosynthesis","volume":"55","author":"Gelse","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1215","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0021-9258(18)70317-7","article-title":"Studies on the structure of the vitreous body. VI. Biochemical changes during development","volume":"234","author":"Balazs","year":"1959","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1220","first-page":"159","article-title":"Vitreous structure. I. Distribution of hyaluronate and protein","volume":"11","author":"Swann","year":"1972","journal-title":"Invest Ophthalmol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1225","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.survophthal.2015.11.008","article-title":"Vitreous floaters: Etiology, diagnostics, and management","volume":"61","author":"Milston","year":"2016","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejpb.2020.05.005_b1230","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2147\/OPTH.S143898","article-title":"Posterior vitreous detachment -Prevalence of and risk factors for retinal tears","volume":"11","author":"Bond-Taylor","year":"2017","journal-title":"Clin Ophthalmol."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1235","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.preteyeres.2010.07.001","article-title":"Remodelling of the human vitreous and vitreoretinal interface\u2013a dynamic process","volume":"29","author":"Ponsioen","year":"2010","journal-title":"Prog Retin Eye Res."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1240","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.survophthal.2010.09.001","article-title":"Vitreous Substitutes: A Comprehensive Review","volume":"56","author":"Kleinberg","year":"2011","journal-title":"Surv. Ophthalmol."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2020.05.005_b1245","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijpharm.2018.07.070","article-title":"Diffusion through the ex vivo vitreal body \u2013 Bovine, porcine, and ovine models are poor surrogates for the human vitreous","volume":"550","author":"Shafaie","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1250","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1167\/iovs.10-5813","article-title":"Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles","volume":"52","author":"Tan","year":"2011","journal-title":"Investig Ophthalmol Vis Sci."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b1255","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/jps.24480","article-title":"The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development","volume":"104","author":"Awwad","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.05.005_b1260","first-page":"6407","article-title":"Artificial vitreous humor for in vitro experiments","volume":"2007","author":"Kummer","year":"2007","journal-title":"Conf. Proc. Int. Conf. IEEE Eng. Med. Biol. Soc."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1265","first-page":"72","article-title":"Biophysical Evaluation of Vitreous Humor, Its Constituents and Substitutes","volume":"20","author":"Suri","year":"2006","journal-title":"Trends Biomater. Artif. Organs"},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1270","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.actbio.2010.10.030","article-title":"Towards an ideal biomaterial for vitreous replacement: Historical overview and future trends","volume":"7","author":"Baino","year":"2011","journal-title":"Acta Biomater."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b1275","article-title":"Wan C. Local versus general anaesthesia for adults undergoing pars plana vitrectomy surgery","volume":"2016","author":"Licina","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b1280","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/eye.2008.20","article-title":"25-, 23-, or 20-Gauge Instrumentation for Vitreous Surgery?","volume":"22","author":"Williams","year":"2008","journal-title":"Eye."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1285","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1167\/iovs.09-3582","article-title":"Vitreous VEGF clearance is increased after vitrectomy","volume":"51","author":"Lee","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b1290","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0161-6420(85)33838-1","article-title":"Amphotericin clearance in vitrectomized versus nonvitrectomized eyes","volume":"92","author":"Doft","year":"1985","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1295","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0002-9394(14)73646-3","article-title":"Effects of inflammation and surgery on amikacin levels in the vitreous cavity","volume":"115","author":"Mandell","year":"1993","journal-title":"Am. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1300","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00006982-199515050-00010","article-title":"Vancomycin levels after intravitreal injection. Effects of inflammation and surgery","volume":"15","author":"Aguilar","year":"1995","journal-title":"Retina."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1305","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/jop.1998.14.555","article-title":"Pharmacokinetics of intravitreal vancomycin in normal and infected rabbit eyes","volume":"14","author":"Coco","year":"1998","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1310","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0161-6420(85)34063-0","article-title":"Clearance of Intravitreal Fluorouracil","volume":"92","author":"Jarus","year":"1985","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1315","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/IAE.0b013e3182753b12","article-title":"Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy","volume":"33","author":"Christoforidis","year":"2013","journal-title":"Retina."},{"key":"10.1016\/j.ejpb.2020.05.005_b1320","unstructured":"National Eye Institute. National Eye Institute. https:\/\/www.flickr.com\/photos\/nationaleyeinstitute\/albums\/72157646829197286."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b1325","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1167\/iovs.12-10164","article-title":"Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys","volume":"53","author":"Kakinoki","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"14","key":"10.1016\/j.ejpb.2020.05.005_b1330","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1335","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1340","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: Results from 2 phase iii randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b1345","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1350","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/aos.13160","article-title":"Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes","volume":"95","author":"Laugesen","year":"2017","journal-title":"Acta Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1355","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2007.02.048","article-title":"Bevacizumab (Avastin) for Diabetic Macular Edema in Previously Vitrectomized Eyes","volume":"144","author":"Yanyali","year":"2007","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-50324-8","article-title":"Characterization of artificially re-pigmented ARPE-19 retinal pigment epithelial cell model","volume":"9","author":"Hellinen","year":"2019","journal-title":"Sci. Rep."},{"issue":"July","key":"10.1016\/j.ejpb.2020.05.005_b1365","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejps.2017.07.027","article-title":"Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts","volume":"109","author":"Pelkonen","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1370","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1600-0749.1993.tb00612.x","article-title":"Role of melanin as a scavenger of active oxygen species","volume":"6","author":"Bustamante","year":"1993","journal-title":"Pigment Cell Res."},{"key":"10.1016\/j.ejpb.2020.05.005_b1375","first-page":"23","article-title":"Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes","author":"Durairaj","year":"201298","journal-title":"Exp. Eye Res."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1380","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/jop.1992.8.35","article-title":"Quantitative determination of the melanin contents in ocular tissues from human blue and brown eyes","volume":"8","author":"Menon","year":"1992","journal-title":"J Ocul Pharmacol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1385","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1167\/iovs.12-10169","article-title":"Assessing a novel depot delivery strategy for noninvasive administration of VEGF\/PDGF RTK inhibitors for ocular neovascular disease","volume":"54","author":"Robbie","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1390","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1167\/iovs.04-1051","article-title":"Permeability of retinal pigment epithelium: Effects of permeant molecular weight and lipophilicity","volume":"46","author":"Pitk\u00e4nen","year":"2005","journal-title":"Investig Ophthalmol Vis Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1395","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1167\/iovs.07-0214","article-title":"Effect of Eye Pigmentation on Transscleral Drug Delivery","volume":"49","author":"Cheruvu","year":"2008","journal-title":"Invest Ophthalmol."},{"key":"10.1016\/j.ejpb.2020.05.005_b1400","first-page":"405","article-title":"The reaction of uveal pigment in vitro with polycyclic compounds","volume":"3","author":"Potts","year":"1964","journal-title":"Invest Ophthalmol."},{"issue":"March","key":"10.1016\/j.ejpb.2020.05.005_b1405","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jconrel.2018.05.034","article-title":"Melanin targeting for intracellular drug delivery: Quantification of bound and free drug in retinal pigment epithelial cells","volume":"283","author":"Rimpel\u00e4","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2020.05.005_b1410","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.toxrep.2014.10.019","article-title":"Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies","volume":"1","author":"Schroeder","year":"2014","journal-title":"Toxicol Reports."},{"issue":"7101","key":"10.1016\/j.ejpb.2020.05.005_b1415","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(59)90604-X","article-title":"Retinopathy following chloroquine therapy","volume":"274","author":"Hobbs","year":"1959","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2020.05.005_b1420","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/10915810290169873","article-title":"Retinal Pigment Epithelium Melanin and Ocular Toxicity","volume":"21","author":"Dayhaw-barker","year":"2002","journal-title":"Int J Toxicol."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b1425","first-page":"671","article-title":"An explanation for the long duration of mydriatic effect of atropine in eye","volume":"15","author":"Salazar","year":"1976","journal-title":"Invest Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1430","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0378-5173(84)90132-7","article-title":"Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye. II. Drug response","volume":"19","author":"Urtti","year":"1984","journal-title":"Int J Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1435","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations","volume":"12","author":"Varela-Fern\u00e1ndez","year":"2020","journal-title":"Pharmaceutics."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1440","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11596-006-0426-6","article-title":"Comparative Study of Two Vitreous Humor Sampling Methods in Rabbits","volume":"26","author":"Lan","year":"2006","journal-title":"J Huazhong Univ Sci Technol."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1445","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/exer.2000.0953","article-title":"Ocular pharmacokinetics in rabbits using a novel dual probe microdialysis technique","volume":"72","author":"Macha","year":"2001","journal-title":"Exp. Eye Res."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2020.05.005_b1450","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2004.05.028","article-title":"Validation of an ocular microdialysis technique in rabbits with permanently implanted vitreous probes: systemic and intravitreal pharmacokinetics of fluorescein","volume":"281","author":"Anand","year":"2004","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b1455","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1167\/iovs.09-3569","article-title":"Intravitreal infliximab clearance in a rabbit model: different sampling methods and assay techniques","volume":"50","author":"Giansanti","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1460","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1089\/108076801753266866","article-title":"Ocular pharmacokinetics of cephalosporins using microdialysis","volume":"17","author":"Macha","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1465","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/00006982-199909000-00013","article-title":"Ocular toxicity of intravitreal clarithromycin","volume":"19","author":"Unal","year":"1999","journal-title":"Retina."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1470","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/jop.1999.15.455","article-title":"Microdialysis for Pharmacokinetic Studies of Ceftazidime in Rabbit Vitreous","volume":"15","author":"Waga","year":"1999","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1475","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tibtech.2006.04.001","article-title":"Scientific and regulatory considerations on the immunogenicity of biologics","volume":"24","author":"Shankar","year":"2006","journal-title":"Trends Biotechnol."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1480","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cbpa.2009.04.627","article-title":"Engineered protein scaffolds as next-generation antibody therapeutics","volume":"13","author":"Gebauer","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b1485","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1128\/AAC.00440-09","article-title":"Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics","volume":"53","author":"Brinch","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2020.05.005_b1490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.10.026","article-title":"Single ocular injection of a sustained-release anti-VEGF delivers 6 months pharmacokinetics and efficacy in a primate laser CNV model","volume":"244","author":"Adamson","year":"2016","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b1495","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s11095-010-0172-0","article-title":"Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice","volume":"27","author":"van Beers","year":"2010","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1500","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0002-9394(14)76693-0","article-title":"Analysis of local antibody productionin the vitreous humor of patients with severe uveitis","volume":"112","author":"Baarsma","year":"1991","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1505","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejpb.2005.01.009","article-title":"Cell culture models of the ocular barriers","volume":"60","author":"Hornof","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1510","first-page":"169","article-title":"In vitro - in vivo correlation: from theory to applications","volume":"9","author":"Emami","year":"2006","journal-title":"J Pharm Pharm Sci."},{"key":"10.1016\/j.ejpb.2020.05.005_b1515","first-page":"1","article-title":"General pharmacokinetic model for topically administered ocular drug dosage forms","volume":"56","author":"Deng","year":"2016","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1520","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0939-6411(01)00123-0","article-title":"Reconstruction of an in vitro cornea and its use for drug permeation studies from different formulations containing pilocarpine hydrochloride","volume":"51","author":"Tegtmeyer","year":"2001","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1525","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/biores.2016.0008","article-title":"In vitro cell models for ophthalmic drug development applications","volume":"5","author":"Shafaie","year":"2016","journal-title":"Biores. Open Access"},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1530","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jop.2009.0132","article-title":"In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment","volume":"26","author":"Missel","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1535","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14227\/DT120205P17","article-title":"The flow through cell methodology in the evaluation of intralumenal drug release characteristics","volume":"12","author":"Fotaki","year":"2005","journal-title":"Dissolution Technol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1540","doi-asserted-by":"crossref","first-page":"46","DOI":"10.14227\/DT180411P46","article-title":"Flow-through cell apparatus (USP Apparatus 4): Operation and features","volume":"18","author":"Fotaki","year":"2011","journal-title":"Dissolution Technol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1545","first-page":"201","article-title":"Dissolution and dissolution apparatus: a review","volume":"1","author":"Uddin","year":"2011","journal-title":"Int J Curr Biomed Pharm Res."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1550","doi-asserted-by":"crossref","first-page":"6","DOI":"10.14227\/DT230316P6","article-title":"A brief review of the FDA dissolution methods database","volume":"23","author":"Shohin","year":"2016","journal-title":"Dissolution Technol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1555","doi-asserted-by":"crossref","first-page":"25","DOI":"10.14227\/DT140207P25","article-title":"Application of USP apparatus 7 to in vitro drug release in scopolamine transdermal systems","volume":"14","author":"Zhou","year":"2007","journal-title":"Dissolution Technol."},{"key":"10.1016\/j.ejpb.2020.05.005_b1560","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1874364101004010052","article-title":"Aqueous humor dynamics: a review","volume":"4","author":"Goel","year":"2010","journal-title":"Open Ophthalmol J."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b1565","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1167\/iovs.06-0154","article-title":"Concordance of aqueous humor flow in the morning and at night in normal humans","volume":"47","author":"Radenbaugh","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b1570","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1021\/acs.molpharmaceut.7b00164","article-title":"Ocular pharmacokinetics of therapeutic antibodies given by intravitreal injection: estimation of retinal permeabilities using a 3-compartment semi-mechanistic model","volume":"14","author":"Hutton-Smith","year":"2017","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1575","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.drudis.2013.08.002","article-title":"Toward the practical implementation of eye-related bioavailability prediction models","volume":"19","author":"Pepi\u0107","year":"2014","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.ejpb.2020.05.005_b1580","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0014-4835(66)80029-5","article-title":"Posterior Drainage of the Intraocular Fluid from the Vitreous","volume":"5","author":"Hayreh","year":"1966","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2020.05.005_b1585","unstructured":"WS D-E. The nature of the vitreous body, Monograph supplement IV. Br J Ophthalmol. 1930;Monograph."},{"key":"10.1016\/j.ejpb.2020.05.005_b1590","first-page":"63","article-title":"Meridional flow from the corona ciliaris through the pararetinal zone of the rabbit vitreous","volume":"2","author":"Fowlks","year":"1963","journal-title":"Invest Ophthalmol."},{"key":"10.1016\/j.ejpb.2020.05.005_b1595","doi-asserted-by":"crossref","unstructured":"Kompella UB, Edelhauser HF. Drug Product Development for the Back of the Eye. Vol 2. (Kompella UB, Edelhauser HF, eds.). Boston, MA: Springer US; 2011.","DOI":"10.1007\/978-1-4419-9920-7"},{"key":"10.1016\/j.ejpb.2020.05.005_b1600","doi-asserted-by":"crossref","unstructured":"Scholes GN, O\u2019Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol (Chicago, Ill 1960) 1985; 103(10): 1567\u20131569.","DOI":"10.1001\/archopht.1985.01050100143037"},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1605","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1023\/A:1007517912927","article-title":"Permeability and diffusion in vitreous humor: implications for drug delivery","volume":"17","author":"Xu","year":"2000","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1610","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10237-012-0398-3","article-title":"Saccade movements effect on the intravitreal drug delivery in vitreous substitutes: a numerical study","volume":"12","author":"Modareszadeh","year":"2013","journal-title":"Biomech. Model. Mechanobiol."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1615","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2005.03.010","article-title":"Evaluation of coupled convective\u2013diffusive transport of drugs administered by intravitreal injection and controlled release implant","volume":"105","author":"Park","year":"2005","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1620","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1023\/A:1022207026982","article-title":"Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor","volume":"20","author":"Stay","year":"2003","journal-title":"Pharm. Res."},{"issue":"19","key":"10.1016\/j.ejpb.2020.05.005_b1625","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1088\/0031-9155\/50\/19\/021","article-title":"Experimental investigation of vitreous humour motion within a human eye model","volume":"50","author":"Repetto","year":"2005","journal-title":"Phys. Med. Biol."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b1630","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1088\/0031-9155\/52\/7\/016","article-title":"Eye rotation induced dynamics of a Newtonian fluid within the vitreous cavity: the effect of the chamber shape","volume":"52","author":"Stocchino","year":"2007","journal-title":"Phys. Med. Biol."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b1635","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s11095-012-0721-9","article-title":"Simulating Intravitreal Injections in Anatomically Accurate Models for Rabbit, Monkey, and Human Eyes","volume":"29","author":"Missel","year":"2012","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b1640","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/pharmaceutics11080371","article-title":"Hydrodynamics of Intravitreal Injections into Liquid Vitreous Substitutes","volume":"11","author":"Henein","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2020.05.005_b1650","doi-asserted-by":"crossref","unstructured":"Loch C, Nagel S, Guthoff R, Seidlitz A, Weitschies W. The Vitreous Model \u2013 a new in vitro test method simulating the vitreous body Model characterization. 2012;57:281-284.","DOI":"10.1515\/bmt-2012-4106"},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1655","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jps.23808","article-title":"Simulation of drug distribution in the vitreous body after local drug application into intact vitreous body and in progress of posterior vitreous detachment","volume":"103","author":"Loch","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.05.005_b1660","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejpb.2015.04.033","article-title":"Evaluation of protein drug stability with vitreous humor in a novel ex-vivo intraocular model","volume":"95","author":"Patel","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2020.05.005_b1665","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2017.02.047","article-title":"Sustained release ophthalmic dexamethasone: In vitro in vivo correlations derived from the PK-Eye","volume":"522","author":"Awwad","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2020.05.005_b1670","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijpharm.2016.02.015","article-title":"Electrospun formulations of acyclovir, ciprofloxacin and cyanocobalamin for ocular drug delivery","volume":"502","author":"Baskakova","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.05.005_bib1978","doi-asserted-by":"crossref","DOI":"10.3390\/nano9101461","article-title":"Thermosensitive nanocomposite hydrogels for intravitreal delivery of cefuroxime","volume":"9","author":"Sapino","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejpb.2020.05.005_bib1979","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejpb.2020.01.008","article-title":"Validation of hyaluronic acid-agar-based hydrogels as vitreous humor Tmimetics for in vitro drug and particle migration evaluations","volume":"148","author":"Thakur","year":"2020","journal-title":"Eur. J. Pharmaceut. Biopharmaceut."},{"key":"10.1016\/j.ejpb.2020.05.005_b1675","doi-asserted-by":"crossref","unstructured":"V.K. Goel, E. Nyman, Computational modeling and finite element analysis, Spine (Phila Pa 1976) 2016; 41(7): S6-S7.","DOI":"10.1097\/BRS.0000000000001421"},{"key":"10.1016\/j.ejpb.2020.05.005_b1680","unstructured":"Guidance for Industry--- Exposure-Response Relationships --- Study Design, Data Analysis, and Regulatory Applications.; 2003."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1685","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/jop.1997.13.445","article-title":"Drug distribution in the vitreous humor of the human eye: the effects of aphakia and changes in retinal permeability and vitreous diffusivity","volume":"13","author":"Friedrich","year":"1997","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"23\u201324","key":"10.1016\/j.ejpb.2020.05.005_b1690","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1016\/j.ijheatmasstransfer.2008.04.053","article-title":"Computational modeling of intravitreal drug delivery in the vitreous chamber with different vitreous substitutes","volume":"51","author":"Kathawate","year":"2008","journal-title":"Int. J. Heat Mass Transf."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b1695","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1167\/iovs.17-23632","article-title":"Three-dimensional transport model for intravitreal and suprachoroidal drug injection","volume":"59","author":"Zhang","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1700","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13362-016-0031-7","article-title":"Mathematical assessment of drug build-up in the posterior eye following transscleral delivery","volume":"6","author":"Causin","year":"2016","journal-title":"J. Math. Ind."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1705","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10439-005-8974-7","article-title":"Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging","volume":"33","author":"Kim","year":"2005","journal-title":"Ann. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1710","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0169-409X(01)00187-9","article-title":"Pharmacokinetic model for in vivo\/in vitro correlation of intravitreal drug delivery","volume":"52","author":"Tojo","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b1715","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1248\/cpb.52.1290","article-title":"A pharmacokinetic model for ocular drug delivery","volume":"52","author":"Tojo","year":"2004","journal-title":"Chem Pharm Bull (Tokyo)."},{"issue":"4","key":"10.1016\/j.ejpb.2020.05.005_b1720","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0002-9394(01)01408-8","article-title":"Accuracy and precision of intraocular injection volume","volume":"133","author":"Raju","year":"2002","journal-title":"Am. J. Ophthalmol."},{"issue":"5 Suppl","key":"10.1016\/j.ejpb.2020.05.005_b1725","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00006982-200410001-00002","article-title":"Evolving guidelines for intravitreous injections","volume":"24","author":"Aiello","year":"2004","journal-title":"Retina."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1730","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0092-8240(78)80041-X","article-title":"A hydrodynamic model of aqueous flow in the posterior chamber of the eye","volume":"40","author":"Friedland","year":"1978","journal-title":"Bull. Math. Biol."},{"issue":"6","key":"10.1016\/j.ejpb.2020.05.005_b1735","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","article-title":"Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents","volume":"146","author":"Kim","year":"2008","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1740","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/IAE.0b013e3181b094cf","article-title":"Experimental model of intravitreal injection techniques","volume":"30","author":"Hubschman","year":"2010","journal-title":"Retina."},{"issue":"5\u20136","key":"10.1016\/j.ejpb.2020.05.005_b1745","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.ejpb.2020.05.005_b1750","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mbs.2014.06.008","article-title":"Computational modeling of drug distribution in the posterior segment of the eye: effects of device variables and positions","volume":"255","author":"Jooybar","year":"2014","journal-title":"Math. Biosci."},{"issue":"8","key":"10.1016\/j.ejpb.2020.05.005_b1755","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00204-011-0718-x","article-title":"Alternatives to animal testing: Current status and future perspectives","volume":"85","author":"Liebsch","year":"2011","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejpb.2020.05.005_b1760","article-title":"Statistics of Scientific P Rocedur Es on Living Animals Great","author":"Home Office","year":"2011","journal-title":"Britain"},{"key":"10.1016\/j.ejpb.2020.05.005_b1765","unstructured":"Clemence M, Leaman J. Public Attitudes to Animal Research in 2016.; 2016. http:\/\/www.ipsos-mori.com\/terms."},{"key":"10.1016\/j.ejpb.2020.05.005_b1770","unstructured":"Ipsos. Public Attitudes to Animal Research in 2018.; 2018. http:\/\/www.ipsos-mori.com\/http:\/\/www.ipsos-mori.com\/."},{"key":"10.1016\/j.ejpb.2020.05.005_b1775","unstructured":"NC3Rs. Animals in drug discovery and development. https:\/\/www.nc3rs.org.uk\/animals-drug-discovery-and-development."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1780","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.yrtph.2007.11.009","article-title":"A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development","volume":"50","author":"Robinson","year":"2008","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.ejpb.2020.05.005_b1785","unstructured":"International Conference on Harmonisation (ICH). ICH M3 (R2) - Non-clinical Safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. Guideline. 2009;3(R2):31. http:\/\/www.ich.org\/products\/guidelines\/multidisciplinary\/article\/multidisciplinary-guidelines.html."},{"key":"10.1016\/j.ejpb.2020.05.005_b1790","unstructured":"ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). http:\/\/www.ich.org\/products\/guidelines\/safety\/safety-single\/article\/guidance-on-nonclinical-safety-studies-for-the-conduct-of-human-clinical-trials-and-marketing-author.html."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1795","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/19420862.2016.1145331","article-title":"Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges","volume":"8","author":"Chapman","year":"2016","journal-title":"MAbs."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1800","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cyto.2010.04.008","article-title":"In vitro cytokine release assays for predicting cytokine release syndrome: The current state-of-the-science. Report of a European Medicines Agency Workshop","volume":"51","author":"Vidal","year":"2010","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b1805","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/0960327115598410","article-title":"Animals and the 3Rs in toxicology research and testing","volume":"34","author":"Stokes","year":"2015","journal-title":"Hum. Exp. Toxicol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1810","first-page":"198","article-title":"Pioneering better science through the 3Rs: An introduction to the National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs)","volume":"54","author":"Burden","year":"2015","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"issue":"s1","key":"10.1016\/j.ejpb.2020.05.005_b1815","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S0007114517002227","article-title":"The 3Rs in research: A contemporary approach to replacement, reduction and refinement","volume":"120","author":"MacArthur","year":"2018","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.ejpb.2020.05.005_b1820","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.expneurol.2015.02.024","article-title":"Statistical considerations for preclinical studies","volume":"270","author":"Aban","year":"2015","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1825","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1740774515625964","article-title":"Key cost drivers of pharmaceutical clinical trials in the United States","volume":"13","author":"Sertkaya","year":"2016","journal-title":"Clin Trials."},{"key":"10.1016\/j.ejpb.2020.05.005_b1830","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"10.1016\/j.ejpb.2020.05.005_b1835","unstructured":"Centre for Drug Evaluation and Research (CDER), FDA Pharmacology Review for BLA Application 125156.; 2006."},{"key":"10.1016\/j.ejpb.2020.05.005_b1840","unstructured":"Centre for Drug Evaluation and Research (CDER), FDA Pharmacology Review for BLA Application 125387.; 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022368Orig1s000PharmR.pdf."},{"issue":"11","key":"10.1016\/j.ejpb.2020.05.005_b1845","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: Systematic review and meta-analysis","volume":"132","author":"Thulliez","year":"2014","journal-title":"JAMA Ophthalmol."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b1850","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/IAE.0000000000002004","article-title":"Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for diabetic macular edema","volume":"38","author":"Hirano","year":"2018","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1855","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajo.2009.06.014","article-title":"Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies","volume":"148","author":"Csaky","year":"2009","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2020.05.005_b1860","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b1865","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.ophtha.2016.06.053","article-title":"Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death","volume":"123","author":"Yashkin","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2020.05.005_b1870","unstructured":"Centre for Drug Evaluation and Research (CDER), FDA Medical Review for NDA022315., 2009."},{"key":"10.1016\/j.ejpb.2020.05.005_b1875","unstructured":"Centre for Drug Evaluation and Research (CDER), FDA Medical Review for NDA201932, 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125559Orig1s000MedR.pdf."},{"key":"10.1016\/j.ejpb.2020.05.005_b1880","first-page":"41","article-title":"Intravitreal triamcinolone for intraocular inflammation and associated macular edema","volume":"3","author":"Couch","year":"2009","journal-title":"Clin Ophthalmol."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b1885","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1097\/IAE.0b013e318214d076","article-title":"Preservative-free triamcinolone acetonide injectable suspension versus \u201ctraditional\u201d triamcinolone preparations: impact of aggregate size on retinal biocompatibility","volume":"31","author":"Spitzer","year":"2011","journal-title":"Retina."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1890","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/2040622315590319","article-title":"Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema","volume":"6","author":"Mehta","year":"2015","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.ejpb.2020.05.005_b1895","article-title":"Intravitreal steroids for the treatment of retinal diseases","author":"Sarao","year":"20142014","journal-title":"Sci. World J."},{"issue":"9","key":"10.1016\/j.ejpb.2020.05.005_b1900","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/eye.2013.139","article-title":"Quality of bevacizumab compounded for intravitreal administration","volume":"27","author":"Palmer","year":"2013","journal-title":"Eye (Lond)."},{"issue":"5","key":"10.1016\/j.ejpb.2020.05.005_b1905","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00417-007-0754-7","article-title":"Intraocular inflammation following intravitreal injection of bevacizumab","volume":"246","author":"Bakri","year":"2008","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol."},{"issue":"12","key":"10.1016\/j.ejpb.2020.05.005_b1910","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/eye.2009.7","article-title":"Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection","volume":"23","author":"Artunay","year":"2009","journal-title":"Eye."},{"issue":"3","key":"10.1016\/j.ejpb.2020.05.005_b1915","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/IAE.0b013e3181bd2d51","article-title":"Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch","volume":"30","author":"Yamashiro","year":"2010","journal-title":"Retina."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1920","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/IAE.0b013e3181baf691","article-title":"Toxic vitreitis outbreak after intravitreal injection","volume":"30","author":"Ness","year":"2010","journal-title":"Retina."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1925","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ajo.2011.11.035","article-title":"An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab","volume":"153","author":"Goldberg","year":"2012","journal-title":"Am. J. Ophthalmol."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b1930","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/IAE.0b013e31816c6868","article-title":"Intravitreal silicone oil droplets after intravitreal drug injections","volume":"28","author":"Bakri","year":"2008","journal-title":"Retina."},{"issue":"7","key":"10.1016\/j.ejpb.2020.05.005_b1935","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamaophthalmol.2017.1815","article-title":"Incidence of presumed silicone oil droplets in the vitreous cavity after intravitreal bevacizumab injection with insulin syringes","volume":"135","author":"Khurana","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ejpb.2020.05.005_b1940","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajoc.2017.07.009","article-title":"Silicone oil droplets following intravitreal bevacizumab injections","volume":"10","author":"Yu","year":"2018","journal-title":"Am. J. Ophthalmol. Case Reports."},{"issue":"10","key":"10.1016\/j.ejpb.2020.05.005_b1945","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1097\/IAE.0000000000001809","article-title":"Contamination of anti-VEGF drugs for intravitreal injection how do repackaging and newly developed syringes affect the amount of silicone oil droplets and protein aggregates?","volume":"38","author":"Schargus","year":"2018","journal-title":"Retina."},{"issue":"2","key":"10.1016\/j.ejpb.2020.05.005_b1950","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: Effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2020.05.005_b1955","unstructured":"E. Poku, J. Rathbone, E. Everson-Hock, et al., Bevacizumab in Eye Conditions: Issues Related to Quality, Use, Efficacy and Safety, 2012."},{"key":"10.1016\/j.ejpb.2020.05.005_b1960","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Mixing , Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application. Guidance for Industry, 2018."},{"key":"10.1016\/j.ejpb.2020.05.005_b1965","unstructured":"U.S. Food and Drug Administration. A case of hemorrhagic occlusive retinal vasculitis (HORV) following intraocular injections of a compounded triamcinolone, moxifloxacin, and vancomycin formulation. https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/PharmacyCompounding\/ucm578514.htm. Published 2017."},{"key":"10.1016\/j.ejpb.2020.05.005_b1970","unstructured":"U.S. Food and Drug Administration. FDA Center for Drug Evaluation and Research (CDER). Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route. Guidance for Industry and Review Staff.; 2015. https:\/\/www.fda.gov\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm065014.htm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120301326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120301326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:38:45Z","timestamp":1760546325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641120301326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":400,"alternative-id":["S0939641120301326"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.05.005","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical challenges for developing long acting intravitreal medicines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}